Antimicrobial Agents Practice Questions

Q: A 48-year-old male with a 15-year history of poorly controlled hypertension and type 2 diabetes mellitus presents with generalized facial and leg swelling and moderately increased albuminuria. Which of the following medications should not be prescribed to this patient?

Tenofovir. ### **Explanation** **Correct Option: D. Tenofovir** The patient presents with long-standing hypertension and diabetes mellitus, complicated by generalized edema and albuminuria. This clinical picture is highly suggestive of **Diabetic Nephropathy** and chronic kidney disease (CKD). **Tenofovir Disoproxil Fumarate (TDF)** is a Nucleotide Reverse Transcriptase Inhibitor (NRTI) known for its potential **nephrotoxicity**. It is primarily excreted by the kidneys via glomerular filtration and active tubular secretion. TDF can cause proximal renal tubular dysfunction (Fanconi Syndrome) and a decline in the Glomerular Filtration Rate (GFR). In a patient with pre-existing renal compromise due to diabetes and hypertension, Tenofovir is contraindicated or requires extreme caution and dose adjustment. (Note: Tenofovir Alafenamide (TAF) is a newer prodrug with significantly lower renal toxicity). **Analysis of Incorrect Options:** * **A. Dolutegravir:** An Integrase Strand Transfer Inhibitor (INSTI). While it can cause a slight increase in serum creatinine by inhibiting the OCT2 transporter, it does not cause actual renal injury or affect GFR. * **B & C. Lamivudine and Emtricitabine:** These are NRTIs that are generally considered renal-safe. While they require dose adjustments in patients with low creatinine clearance, they are not inherently nephrotoxic and are not contraindicated in the same manner as Tenofovir. ### **High-Yield Clinical Pearls for NEET-PG:** 1. **Tenofovir Toxicity:** Classically presents as **Fanconi Syndrome** (proteinuria, glucosuria, phosphaturia, and metabolic acidosis). 2. **Drug of Choice:** In HIV patients with renal impairment, **Abacavir** is often preferred over Tenofovir (provided the patient is HLA-B*5701 negative). 3. **Monitoring:** Always check baseline Creatinine and Urine Protein before starting TDF-based regimens. 4. **Mnemonic:** "Tenofovir targets the Tubules" (Proximal Convoluted Tubule).

Q: Pseudomembranous colitis is associated with which of the following medications?

Clindamycin. **Explanation:** **Pseudomembranous colitis (PMC)** is caused by the overgrowth of *Clostridioides difficile* (formerly *Clostridium*), which produces toxins (Toxin A and B) that damage the colonic mucosa. This occurs when the normal gut flora is suppressed by broad-spectrum antibiotics. **Why Clindamycin is the Correct Answer:** While almost any antibiotic can trigger PMC, **Clindamycin** is the classic agent most strongly associated with it in medical literature and exams. It significantly disrupts the anaerobic balance of the colon, creating an ideal environment for *C. difficile* to proliferate. **Analysis of Incorrect Options:** * **Vancomycin (Option A):** Oral Vancomycin is actually a **treatment** of choice for PMC, not a common cause. It is not absorbed systemically and acts locally in the gut to kill *C. difficile*. * **Lincomycin (Option B):** Although in the same class (Lincosamides) as Clindamycin, it is less commonly used in modern clinical practice and is not the "textbook" answer for this association. * **Rovamycin (Option C):** This is Spiramycin (a macrolide), primarily used for Toxoplasmosis. It is not a major culprit for PMC. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Cause:** While Clindamycin is the "classic" answer, in terms of absolute frequency, **Amoxicillin** and **Cephalosporins** (3rd generation) cause more cases due to their higher volume of use. * **Diagnosis:** Gold standard is the detection of *C. difficile* toxins in stool or visualization of "pseudomembranes" on sigmoidoscopy. * **Treatment:** First-line treatment is **Oral Vancomycin** or **Fidaxomicin**. Metronidazole is now reserved for non-severe cases if other options are unavailable. * **Drug of Choice for MRSA:** Clindamycin is often used for CA-MRSA, but always monitor the patient for diarrhea.

Q: Which one of the following drugs inhibits bacterial protein synthesis by preventing the translocation step through its interaction with the 50S ribosomal subunit?

Clindamycin. ### Explanation **Correct Option: A. Clindamycin** Clindamycin is a Lincosamide antibiotic that binds to the **50S ribosomal subunit**. Its primary mechanism of action is the inhibition of the **translocation** step (where the peptidyl-tRNA moves from the A-site to the P-site). By blocking this movement, it prevents the elongation of the peptide chain, thereby inhibiting bacterial protein synthesis. **Analysis of Incorrect Options:** * **B. Gentamicin:** This is an Aminoglycoside. It binds to the **30S subunit**, causing mRNA misreading and inhibition of the initiation complex. It does not target the 50S subunit. * **C. Chloramphenicol:** While it binds to the 50S subunit, its specific mechanism is the inhibition of **peptidyl transferase** (the enzyme that forms peptide bonds), not the translocation step. * **D. Imipenem:** This is a Carbapenem (Beta-lactam). It inhibits **cell wall synthesis** by binding to Penicillin-Binding Proteins (PBPs), not protein synthesis. **High-Yield NEET-PG Pearls:** * **Mnemonic for 50S Inhibitors:** **"CCEL"** – **C**hloramphenicol, **C**lindamycin, **E**rythromycin (Macrolides), and **L**inezolid. * **Translocation Inhibitors:** Both Macrolides (e.g., Azithromycin) and Lincosamides (Clindamycin) inhibit translocation. * **Clinical Association:** Clindamycin is the drug of choice for anaerobic infections above the diaphragm but is notoriously associated with **Pseudomembranous colitis** caused by *Clostridioides difficile*. * **Antagonism:** Clindamycin and Macrolides should not be used together as they have overlapping binding sites on the 50S subunit, leading to antagonistic effects.

Q: What is the fastest acting schizontocidal drug among the following?

Artemether. **Explanation:** **Artemether** (an Artemisinin derivative) is the correct answer because Artemisinins are the **fastest-acting** antimalarial drugs currently available. They act by releasing free radicals upon reacting with the heme iron in the parasite's food vacuole, leading to rapid destruction of the parasite. Their primary clinical advantage is the ability to achieve a **3-log (1000-fold) reduction** in parasite biomass within two asexual cycles (48 hours), which is significantly faster than any other class. **Analysis of Incorrect Options:** * **Chloroquine:** While it is a potent and rapidly acting blood schizontocide, its rate of parasite clearance is slower than that of Artemisinins. Furthermore, widespread resistance has limited its efficacy. * **Mefloquine:** This is a slow-acting blood schizontocide with a long half-life. It is primarily used for prophylaxis or as part of combination therapy, but it does not provide the rapid initial kill required in severe cases. * **Proguanil:** This is a slow-acting drug that primarily acts as a dihydrofolate reductase inhibitor. It is mainly used for prophylaxis and has limited efficacy as a standalone blood schizontocide. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For severe/complicated *P. falciparum* malaria, **IV Artesunate** is the drug of choice due to its rapid action. * **ACT:** Artemisinin-based Combination Therapy (e.g., Artemether + Lumefantrine) is the standard for uncomplicated malaria to prevent resistance and ensure complete clearance. * **Short Half-life:** Artemisinins have a very short half-life (~1-2 hours), which is why they must be combined with a long-acting drug (like Lumefantrine or Mefloquine) to prevent recrudescence.

Q: A patient is experiencing difficulty in distinguishing red-green lights. Which of the following drugs is most likely responsible for this side effect?

Ethambutol. ### Explanation **Correct Option: B. Ethambutol** Ethambutol is a first-line antitubercular drug that inhibits the enzyme **arabinosyl transferase**, thereby interfering with mycobacterial cell wall synthesis. The most characteristic and high-yield side effect of Ethambutol is **Retrobulbar Neuritis**. This typically manifests as: 1. **Decreased visual acuity.** 2. **Central scotoma.** 3. **Loss of red-green color discrimination** (often the earliest sign). This toxicity is **dose-dependent** (usually seen at doses >25 mg/kg) and is generally reversible upon discontinuation of the drug. --- ### Why the other options are incorrect: * **A. Capreomycin:** This is an injectable second-line drug (cyclic peptide). Its primary toxicities are **nephrotoxicity** and **ototoxicity** (similar to aminoglycosides), not visual disturbances. * **C. Ethionamide:** This drug is structurally related to Isoniazid. Its major side effects include severe **gastrointestinal irritation**, **hepatotoxicity**, and **hypothyroidism**. While it can rarely cause peripheral neuropathy, it is not classically associated with red-green blindness. * **D. Other second-line agents:** Drugs like Cycloserine (neuropsychiatric issues) or Kanamycin (ototoxicity) do not typically cause optic neuritis. --- ### NEET-PG Clinical Pearls: * **Monitoring:** Patients on Ethambutol should undergo baseline and monthly **Snellen’s chart** and **Ishihara chart** testing. * **Pediatric Caution:** Ethambutol is generally avoided in children young enough that visual acuity cannot be accurately monitored (typically <6 years), though guidelines vary. * **Renal Adjustment:** Since Ethambutol is primarily excreted by the kidneys, the dose must be adjusted in renal failure to prevent accumulation and subsequent ocular toxicity. * **Mnemonic:** **E**thambutol for **E**ye (Optic neuritis).

Q: Which of the following monoclonal antibodies can be used in Clostridium difficile infection?

Bezlotoxumab. **Explanation:** **Correct Answer: D. Bezlotoxumab** **Mechanism and Rationale:** *Clostridium difficile* infection (CDI) causes pathology primarily through the release of two exotoxins: **Toxin A (Enterotoxin)** and **Toxin B (Cytotoxin)**. While antibiotics like Vancomycin or Fidaxomicin target the bacteria itself, **Bezlotoxumab** is a human monoclonal antibody that binds specifically to **Toxin B**. By neutralizing the toxin, it prevents damage to the intestinal mucosa and significantly reduces the risk of **recurrent CDI** in high-risk patients. It is administered as a single intravenous infusion. **Analysis of Incorrect Options:** * **A. Canakinumab:** An **Interleukin-1β (IL-1β) inhibitor** used in systemic juvenile idiopathic arthritis and periodic fever syndromes. * **B. Dupilumab:** An **IL-4 and IL-13 receptor antagonist** used in the management of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. * **C. Certolizumab:** A **TNF-alpha inhibitor** (specifically a PEGylated Fab' fragment) used in Crohn’s disease and rheumatoid arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **Bezlotoxumab vs. Actoxumab:** While Bezlotoxumab targets Toxin B, Actoxumab (targets Toxin A) was also studied but did not show clinical efficacy on its own. * **Drug of Choice for CDI:** Oral **Fidaxomicin** or oral **Vancomycin** are first-line agents. Metronidazole is now reserved for non-severe cases where other options are unavailable. * **Key Side Effect:** Use Bezlotoxumab with caution in patients with **congestive heart failure (CHF)**, as it may exacerbate the condition.

Q: A 37-year-old immunosuppressed patient with renal failure develops sepsis. Which of the following antibiotics, if used, would require a major reduction in dosage?

Tobramycin. **Explanation:** The core concept tested here is the **route of elimination** of antimicrobial agents. In patients with renal failure, drugs primarily excreted unchanged by the kidneys require significant dose adjustments to prevent toxicity. **Why Tobramycin is correct:** Tobramycin is an **Aminoglycoside**. Aminoglycosides are highly polar, water-soluble molecules that are excreted almost entirely (90%+) via **glomerular filtration** in an unchanged form. In renal failure, their clearance decreases proportionally with the Creatinine Clearance (CrCl). Failure to reduce the dose or increase the dosing interval leads to accumulation, significantly increasing the risk of **nephrotoxicity** and **ototoxicity**. **Why the other options are incorrect:** * **Erythromycin:** This macrolide is primarily metabolized by the liver and excreted in the **bile**. No major dose adjustment is needed in renal failure. * **Doxycycline:** Unlike other tetracyclines, doxycycline is excreted mainly via the **feces** (enterohepatic circulation). It is the "tetracycline of choice" in renal failure. * **Isoniazid:** This antitubercular drug undergoes **hepatic acetylation**. While metabolites are excreted renally, a major dose reduction is generally not required unless there is concurrent hepatic impairment. **High-Yield NEET-PG Pearls:** * **"Safe" in Renal Failure:** Ceftriaxone, Doxycycline, Erythromycin, Clindamycin, and Linezolid (no major adjustment). * **Contraindicated in Renal Failure:** Tetracycline (except Doxycycline), Nitrofurantoin, and Nalidixic acid. * **Aminoglycoside Monitoring:** Therapeutic Drug Monitoring (TDM) is essential. They exhibit **concentration-dependent killing** and a significant **post-antibiotic effect (PAE)**.

Q: Thioacetazone has cross-resistance with which of the following drugs?

Ethionamide. **Explanation:** The correct answer is **Ethionamide**. **Why Ethionamide is correct:** Thioacetazone and Ethionamide are both members of the **thioamide** group of antitubercular drugs. They share a similar chemical structure and a common mechanism of action: both act as prodrugs that are activated by the monooxygenase enzyme **EthA**. Once activated, they inhibit the enzyme **InhA** (enoyl-ACP reductase), which is essential for mycolic acid synthesis in the mycobacterial cell wall. Because they utilize the same activation pathway (EthA), a mutation in the *ethA* gene leads to resistance in both drugs, resulting in **cross-resistance** [5]. **Why other options are incorrect:** * **Isoniazid (INH):** While INH also inhibits the InhA enzyme, it is activated by a different enzyme, **KatG** (catalase-peroxidase). Therefore, resistance to INH (usually via KatG mutation) does not automatically confer resistance to Thioacetazone [5]. * **Rifampicin:** This drug acts by inhibiting DNA-dependent RNA polymerase (rpoB gene). Its mechanism is entirely distinct from mycolic acid synthesis inhibitors [4]. * **Ethambutol:** This drug inhibits arabinosyl transferase, interfering with the synthesis of arabinogalactan in the cell wall. It does not share a metabolic pathway or target with Thioacetazone. **High-Yield Clinical Pearls for NEET-PG:** * **Thioacetazone & HIV:** Thioacetazone is strictly contraindicated in HIV-positive patients due to the high risk of life-threatening **Stevens-Johnson Syndrome (SJS)** and Toxic Epidermal Necrolysis (TEN). * **Ethionamide Side Effects:** It is notorious for causing intense GI irritation and a metallic taste [5]. * **Cross-resistance Summary:** Always remember the

Question 1

A 48-year-old male with a 15-year history of poorly controlled hypertension and type 2 diabetes mellitus presents with generalized facial and leg swelling and moderately increased albuminuria. Which of the following medications should not be prescribed to this patient?

Accepted Answer

Tenofovir

Answer

Dolutegravir

Answer

Lamivudine

Answer

Emtricitabine

Question 2

Pseudomembranous colitis is associated with which of the following medications?

Accepted Answer

Clindamycin

Answer

Vancomycin

Answer

Lincomycin

Answer

Rovamycin

Question 3

Which one of the following drugs inhibits bacterial protein synthesis by preventing the translocation step through its interaction with the 50S ribosomal subunit?

Accepted Answer

Clindamycin

Answer

Gentamicin

Answer

Chloramphenicol

Answer

Imipenem

Question 4

What is the fastest acting schizontocidal drug among the following?

Accepted Answer

Artemether

Answer

Mefloquine

Answer

Chloroquine

Answer

Proguanil

Question 5

What is the drug of choice for the treatment of Tularemia?

Accepted Answer

Streptomycin

Answer

Kanamycin

Answer

Neomycin

Answer

Chloramphenicol

Question 6

A patient is experiencing difficulty in distinguishing red-green lights. Which of the following drugs is most likely responsible for this side effect?

Accepted Answer

Ethambutol

Answer

Capreomycin

Answer

Ethionamide

Answer

Other second-line antitubercular agents

Question 7

Which of the following monoclonal antibodies can be used in Clostridium difficile infection?

Accepted Answer

Bezlotoxumab

Answer

Canakinumab

Answer

Dupilumab

Answer

Certolizumab

Question 8

A 37-year-old immunosuppressed patient with renal failure develops sepsis. Which of the following antibiotics, if used, would require a major reduction in dosage?

Accepted Answer

Tobramycin

Answer

Erythromycin

Answer

Doxycycline

Answer

Isoniazid

Question 9

Which of the following drugs CANNOT be used to treat infections caused by Bacteroides fragilis?

Accepted Answer

Amikacin

Answer

Metronidazole

Answer

Trovafloxacin

Answer

Vancomycin

Question 10

Thioacetazone has cross-resistance with which of the following drugs?

Accepted Answer

Ethionamide

Answer

Isoniazid (INH)

Answer

Rifampicin

Answer

Ethambutol

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?